Drug intelligence / Profile preview

Juming Granules

Development stage: Preclinical
Lead developer: He Eye Hospital
Administration: Oral

Overview

Juming Granules (菊明颗粒) is a self-developed traditional Chinese medicine (TCM) formulation in granule form, developed by He Eye Hospital (HSYK) for the treatment of dry eye disease. As an oral medication, it is designed to alleviate the symptoms of dry eye through the synergistic effects of its herbal components. The drug is described by the developer as an innovative, self-researched product that is nearing market launch. While specific mechanistic details are not publicly disclosed, it follows the principles of traditional Chinese medicine to address ocular surface health and tear film stability.

Brand names: Juming Granules
Other names: 菊明颗粒Juming Keli

Beyond the preview

Go deeper on Juming Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juming Granules.

Explore the full profile